{
  "docId": "019de073-7a8f-7069-abd7-4f5a253312a5",
  "docSlug": "7534f8dddd85d538a9efc95a5aebf002",
  "documentTitle": "Aquestive Therapeutics | Results Presentation Deck | 14 slides",
  "authorId": "aquestive-therapeutics",
  "authorName": "Aquestive Therapeutics",
  "documentKindSlug": "deck",
  "documentKindLabel": "Deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.2938006,
  "pageNumber": 6,
  "pageCount": 14,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "other",
  "function": "establish_context",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de073-7a8f-7069-abd7-4f5a253312a5/6",
  "deckHref": "/decks/019de073-7a8f-7069-abd7-4f5a253312a5",
  "deckJsonHref": "/decks/019de073-7a8f-7069-abd7-4f5a253312a5.json",
  "deckAnchorHref": "/decks/019de073-7a8f-7069-abd7-4f5a253312a5#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.03,
        "w": 0.35,
        "x": 0.07,
        "y": 0.495
      },
      "kind": "list",
      "text": "Assessed continued safety and tolerability",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2e4447f9-f836-4d0c-a40e-70911a9ce72b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.75,
        "x": 0.07,
        "y": 0.355
      },
      "kind": "list",
      "text": "Designed to compare pharmacokinetics and pharmacodynamics of: Single doses of AQST-109 to single doses of EpiPen 0.3mg and epi 0.3mg IM injection; Repeat doses of AQST-109 to repeat doses of epi 0.3mg IM injection",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b81247fe-79ad-4da0-bf29-d025b6f1f279",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.45,
        "x": 0.07,
        "y": 0.285
      },
      "kind": "list",
      "text": "Healthy volunteers, randomized, open-label, 5-period trial",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f13714de-f019-4ead-8858-45860bec8708",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.45,
        "x": 0.07,
        "y": 0.19
      },
      "kind": "title",
      "text": "EPIPHAST II: Trial Design and Objectives",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "22c91dbb-dfb7-44e0-8ccc-981342349629",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "19583676-a1ba-4516-8bec-ef0d622bc67c",
      "evidence": "The slide presents information in a list format with bullet points.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 13,
      "from": 3,
      "beatId": "fd64535f-8805-4be0-ab9c-f0396589752f",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document provides relief through presentation of EPIPHAST II trial results, including key takeaways and data, on slides 3-13",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 10,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "b6791be9-182b-48c3-8ddb-65cec4fe9e39",
      "evidence": "The document implies the cost of inaction through presentation of rapid epinephrine delivery and trial results",
      "position": 0,
      "objective": "What is the cost of not using Aquestive Therapeutics' epinephrine product?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}